title: Cardiac side effects of molecular targeted therapies: towards a better dialogue between oncologists and cardiologists.
abstract: Molecular targeted therapies (MTTs) have become a major component of modern management of various hematological and solid malignancies. However, some MTTs have been associated with cardiotoxicity. MTT-induced cardiovascular side effects include left ventricular systolic dysfunction, heart failure, conduction abnormalities, acute coronary syndrome, and hypertension. One of the most threatening complications of MTT, and notably of angiogenic inhibitors, is QT prolongation with the risk of torsades de pointe and sudden death. The precise incidence of cardiovascular events associated with MTT as well as their reversibility are unknown. Here, we summarize what is known about the cardiotoxicity of MTT, emphasizing MTTs that target tyrosine kinases. We have tried to provide both the basic mechanisms underlying specific cardiotoxicities (such as the interruption of specific signaling pathways leading to cardiomyocyte dysfunction and/or death), and offer guidance regarding the optimal way to detect and treat these cardiotoxicities.
authors.affiliation: Saint-Antoine Hospital and University Pierre et Marie Curie VI, Paris, France.
authors.forename: Stephane
authors.initials: S
authors.lastname: Ederhy
authors.forename: Hassan
authors.initials: H
authors.lastname: Izzedine
authors.forename: Christophe
authors.initials: C
authors.lastname: Massard
authors.forename: Ghislaine
authors.initials: G
authors.lastname: Dufaitre
authors.forename: Jean Philippe
authors.initials: JP
authors.lastname: Spano
authors.forename: Gerard
authors.initials: G
authors.lastname: Milano
authors.forename: Catherine
authors.initials: C
authors.lastname: Meuleman
authors.forename: Benjamin
authors.initials: B
authors.lastname: Besse
authors.forename: Franck
authors.initials: F
authors.lastname: Boccara
authors.forename: David
authors.initials: D
authors.lastname: Kahyat
authors.forename: Ariel
authors.initials: A
authors.lastname: Cohen
authors.forename: Jean Charles
authors.initials: JC
authors.lastname: Soria
mesh_terms: D006331:Heart Diseases / Q000139:chemically induced* / Q000175:diagnosis / Q000188:drug therapy; D006801:Humans; D058990:Molecular Targeted Therapy / Q000009:adverse effects*; D009369:Neoplasms / Q000150:complications* / Q000188:drug therapy